div class=trans-pagebuttonPage 1button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5page1jpg target=_blank amp-img class=trans-thumb alt=Page 1: Rationale and design of a randomized double-blind parallel-group study of Terutroban 30 mgday versus aspirin 100 mgday in stroke patients: src=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 2button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5page2jpg target=_blank amp-img class=trans-thumb alt=Page 2: Rationale and design of a randomized double-blind parallel-group study of Terutroban 30 mgday versus aspirin 100 mgday in stroke patients: src=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 3button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5page3jpg target=_blank amp-img class=trans-thumb alt=Page 3: Rationale and design of a randomized double-blind parallel-group study of Terutroban 30 mgday versus aspirin 100 mgday in stroke patients: src=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 4button div class=trans-image a href=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5page4jpg target=_blank amp-img class=trans-thumb alt=Page 4: Rationale and design of a randomized double-blind parallel-group study of Terutroban 30 mgday versus aspirin 100 mgday in stroke patients: src=https:reader038fdokumencomreader038viewer2023032814632dd8e5a5e339e0ed0a4123html5thumbnails4jpg width=142 height=106 layout=responsive amp-imga...